Xellar Biosystems raised $50M in Series A and A+ financing to expand its AI powered organ-on-chip platform for predictive preclinical drug discovery.
Xellar Biosystems is a Wet Artificial Intelligence (AI) biotechnology company, combining machine learning and AI with large-scale wet-lab experiments, tackling the most challenging problem in modern drug discovery – harnessing the complexity of human biology to accelerate drug discovery and development.